PFE Stock Summary and Trading Ideas (Pfizer | NYSE:PFE)

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer trades on the NYSE stock market under the symbol PFE.

As of January 3, 2025, PFE stock price declined to $26.59 with 27,645,892 million shares trading.

PFE has a beta of 0.05, meaning it tends to be less sensitive to market movements. PFE has a correlation of 0.00 to the broad based SPY ETF.

PFE has a market cap of $150.67 billion. This is considered a Large Cap stock.

Last quarter Pfizer reported $18 billion in Revenue and $1.06 earnings per share. This beat revenue expectation by $3 billion and exceeded earnings estimates by $.44.

In the last 3 years, PFE traded as high as $58.55 and as low as $24.48.

The top ETF exchange traded funds that PFE belongs to (by Net Assets): VTI, VOO, SCHD, SPY, IVV.

PFE has underperformed the market in the last year with a return of -4.9%, while the SPY ETF gained +26.7%. In the last 3 month period, PFE fell short of the market, returning -5.6%, while SPY returned +4.4%. However, in the most recent 2 weeks PFE has outperformed the stock market by returning +3.2%, while SPY returned +1.7%.

PFE support price is $26.24 and resistance is $26.98 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PFE shares will trade within this expected range on the day.